Skip to main content

Advertisement

Log in

Comparative study for the virulence of Mycobacterium avium isolates from patients with nodular-bronchiectasis- and cavitary-type diseases

  • Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

Mycobacterium avium (Mav) lung infections, called nodular-bronchiectasis (NB)-type M. avium complex (MAC) disease, are globally increasing. To elucidate whether there are unusual populations of Mav, causing NB-type disease rather than cavitary (CA)-type disease, we compared the virulence of Mav isolates from patients with NB-type (NB-Mav) and those from CA-type (CA-Mav) diseases, based on intracellular growth in various types of human cells. Five strains each of NB-Mav and CA-Mav were compared with each other for their invasiveness and ability to intracellularly replicate in various types of cultured cells of human origin. The two types of Mav isolates showed a similar ability, on average, to replicate in macrophages and lung epithelial cells. Moreover, they showed a similar ability to induce the production of reactive nitrogen intermediates and reactive oxygen intermediates by macrophages and susceptibility to antimicrobial molecules. Therefore, it appears that there is no essential difference in virulence in terms of infectivity to human macrophages and lung cells between Mav strains isolated from NB-MAC disease and those from CA-MAC disease. These findings indicate the importance of further studies to elucidate the mechanism for the establishment of NB-type MAC diseases based on host immunological conditions rather than the pathogenic nature of MAC organisms themselves.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Iseman MD (1989) Mycobacterium avium complex and the normal host: the other side of the coin. N Engl J Med 321:896–898

    Article  CAS  PubMed  Google Scholar 

  2. Prince DS, Peterson DD, Steiner RM et al (1989) Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 321:863–868

    CAS  PubMed  Google Scholar 

  3. Reich JM, Johnson RE (1992) Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome. Chest 101:1605–1609

    Article  CAS  PubMed  Google Scholar 

  4. Okumura M, Iwai K, Ogata H et al (2006) Clinical studies on the pathogenetic factors of cavitary and nodular bronchiectatic types in pulmonary Mycobacterium avium complex disease. J Jap Respir Soc 44:3–11

    Google Scholar 

  5. Okumura M, Iwai K, Ogata H et al (2008) Clinical factors on cavitary and nodular bronchiectatic types in pulmonary Mycobacterium avium complex disease. Intern Med 47:1465–1472

    Article  PubMed  Google Scholar 

  6. Falkinham JO 3rd, Iseman MD, de Haas P et al (2008) Mycobacterium avium in a shower linked to pulmonary disease. J Water Health 6:209–213

    PubMed  Google Scholar 

  7. Wallace RJ Jr, Zhang Y, Brown-Elliott BA et al (2002) Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis. J Infect Dis 186:266–273

    Article  CAS  Google Scholar 

  8. Inagaki T, Nishimori K, Yagi T et al (2009) Comparison of a variable-number tandem-repeat (VNTR) method for typing Mycobacterium avium with mycobacterial interspersed repetitive-unit-VNTR and IS1245 restriction fragment length polymorphism typing. J Clin Microbiol 47:2156–2164

    Article  CAS  PubMed  Google Scholar 

  9. Tomioka H, Sato K, Kajitani H et al (2000) Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother 44:283–286

    Article  CAS  PubMed  Google Scholar 

  10. Tomioka H, Sato K, Sano C et al (2002) Intramacrophage passage of Mycobacterium tuberculosis and M. avium complex alters the drug susceptibilities of the organisms as determined by intracellular susceptibility testing using macrophages and type II alveolar epithelial cells. Antimicrob Agents Chemother 46:519–521

    Article  CAS  PubMed  Google Scholar 

  11. Sato K, Tomioka H, Sano C et al (2003) Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines. J Antimicrob Chemother 52:199–203

    Article  CAS  PubMed  Google Scholar 

  12. Akaki T, Sato K, Tomioka H et al (1997) Effector molecules in expression of the antimicrobial activity of macrophages against Mycobacterium avium complex: roles of reactive nitrogen intermediates, reactive oxygen intermediates, and free fatty acids. J Leukoc Biol 62:795–804

    CAS  PubMed  Google Scholar 

  13. Akaki T, Tomioka H, Shimizu T et al (2000) Comparative roles of free fatty acids with reactive nitrogen intermediates and reactive oxygen intermediates in expression of the anti-microbial activity of macrophages against Mycobacterium tuberculosis. Clin Exp Immunol 121:302–310

    Article  CAS  PubMed  Google Scholar 

  14. Tomioka H, Sano C, Sato K et al (2005) Combined effects of ATP on the therapeutic efficacy of antimicrobial drug regimens against Mycobacterium avium complex infection in mice and roles of cytosolic phospholipase A2-dependent mechanisms in the ATP-mediated potentiation of antimycobacterial host resistance. J Immunol 175:6741–6749

    CAS  PubMed  Google Scholar 

  15. Reich JM, Johnson RE (1992) Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome. Chest 101:1605–1609

    Article  CAS  PubMed  Google Scholar 

  16. Wallace RJ Jr, Zhang Y, Brown BA et al (1998) Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis. Am J Respir Crit Care Med 158:1235–1244

    PubMed  Google Scholar 

  17. Kim RD, Greenberg DE, Ehrmantraut ME et al (2008) Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 178:1066–1074

    Article  CAS  PubMed  Google Scholar 

  18. Bobadilla JL, Macek M Jr, Fine JP et al (2002) Cystic fibrosis: a worldwide analysis of CFTR mutations—correlation with incidence data and application to screening. Hum Mutat 19:575–606

    Article  CAS  PubMed  Google Scholar 

  19. Anzai C, Morokawa N, Okada H et al (2003) CFTR gene mutations in Japanese individuals with congenital bilateral absence of the vas deferens. J Cyst Fibros 2:14–18

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to H. Tomioka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tatano, Y., Yasumoto, K., Shimizu, T. et al. Comparative study for the virulence of Mycobacterium avium isolates from patients with nodular-bronchiectasis- and cavitary-type diseases. Eur J Clin Microbiol Infect Dis 29, 801–806 (2010). https://doi.org/10.1007/s10096-010-0930-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-010-0930-2

Keywords

Navigation